Repository logo
 
Publication

Immunohistochemical marking in the diagnosis of combined hepatocellular and cholangiocellular carcinoma: a systematic review

2025-03Conference poster Open access
Simple item page
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorQuintas, Catarina
dc.contributor.authorAlves, Marta
dc.contributor.authorSilva, Vera
dc.contributor.authorMendonça, Paula
dc.contributor.authorBorges-Ferro, A
dc.date.accessioned2025-04-04T11:15:47Z
dc.date.available2025-04-04T11:15:47Z
dc.date.issued2025-03
dc.description.abstractCombined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare and biologically aggressive primary hepatic neoplasm, accounting for approximately 2% to 5% of liver tumors. This malignant neoplasm is defined by the coexistence of hepatocellular and cholangiocytic differentiation within the same tumor, integrating morphological and molecular features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Its phenotypic heterogeneity contributes to complex clinical behavior and is associated with a poor prognosis, often worse than isolated HCC or CC. Diagnosing cHCC-CCA remains challenging due to overlapping imaging findings and conflicting biomolecular profiles. Currently, the gold standard for definitive diagnosis is histopathological analysis, with immunohistochemistry (IHC) serving as an essential complementary tool to identify the tumor components. Markers such as arginase-1 (Arg-1), HepPar-1, cytokeratin 18 (K18), cytokeratin 7 (K7), and cytokeratin 19 (K19) are commonly employed to aid in tumor characterization. However, variability in marker expression hampers diagnostic standardization. This study aims to systematize existing evidence on the use of Arg-1, HepPar-1, K18, K7, and K19 in the diagnosis of cHCC-CCA, evaluating their impact on the standardization of diagnostic criteria for this carcinoma.por
dc.identifier.citationQuintas C, Alves M, Silva V, Mendonça P, Borges-Ferro A. Immunohistochemical marking in the diagnosis of combined hepatocellular and cholangiocellular carcinoma: a systematic review. In: III Congresso Nacional da BioMedLab, Auditório Prof. Armando Simões dos Santos, Faculdade de Medicina Dentária, Universidade de Lisboa, 7 a 9 de março de 2025.
dc.identifier.urihttp://hdl.handle.net/10400.21/21751
dc.language.isoeng
dc.peerreviewedyes
dc.relation.hasversionhttps://biomedlab.pt/3-congresso/
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHepatic neoplasm
dc.subjectCombined hepatocellular-cholangiocarcinoma
dc.subjectImmunohistochemical marking
dc.subjectSystematic review
dc.titleImmunohistochemical marking in the diagnosis of combined hepatocellular and cholangiocellular carcinoma: a systematic revieweng
dc.typeconference poster
dspace.entity.typePublication
oaire.citation.conferenceDate2025-03
oaire.citation.conferencePlaceLisboa, Portugal
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameBORGES FERRO
person.givenNameAMADEU JOSÉ
person.identifier.ciencia-idFA16-8351-EB4A
person.identifier.orcid0000-0002-3450-5758
relation.isAuthorOfPublicationf823b4bf-d2e4-456e-a7fa-b35180ff403f
relation.isAuthorOfPublication.latestForDiscoveryf823b4bf-d2e4-456e-a7fa-b35180ff403f

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Immunohistochemical marking in the diagnosis of combined hepatocellular and cholangiocellular carcinoma_a systematic review.pdf
Size:
1.38 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.03 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Posters